Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAAs on Erectile Function in HCV
NCT03444272Phase 3Unknown
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sofosbuvir and daclatasvir in hepatitis C (HCV) (2 arms). Primary endpoint: Number of patients with improved erectile functions at 6 months. Status: unknown.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03444272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444272.